Status:
WITHDRAWN
Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
AstraZeneca
Conditions:
Acute Coronary Syndrome
Coronary Artery Disease
Eligibility:
All Genders
18-79 years
Phase:
PHASE4
Brief Summary
Subjects presenting with probable acute coronary syndromes scheduled for cardiac catheterization will be enrolled in this study. Consented subjects will be randomized to receive ticagrelor started wit...
Eligibility Criteria
Inclusion
- Patient Characteristics:
- Males and non-pregnant females \> or equal to 18 and \< or equal to 79 years of age presenting with suspected acute coronary syndrome (unstable angina or NSTEMI)
- Patients likely to be scheduled to undergo coronary angiography with possible percutaneous coronary intervention (PCI)
- Lesion Characteristics on Diagnostic Coronary Angiography:
- De novo lesions in native coronary arteries found by diagnostic coronary angiography
- Angiographic stenosis \<100%
- Reference vessel diameter 2.5 mm - 4.0 mm by visual estimation
Exclusion
- Patient Specific
Key Trial Info
Start Date :
February 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01916902
Start Date
February 1 2014
Last Update
May 26 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114